维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

7篇 您的检索式：作者名="Filot"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	A new Formalism for Failure Diagnosis: Ant Colony Decision Petri Nets 显示文摘	Ciufudean C Graur A Filote C etc	2007	Journal of soft ware2007，2，1：	1
	2	A new Formalism for Failure Diagnosis:Ant Colony Decision Petri Nets显示文摘	Calin Ciufudean Adrian Graur Constantin Filote		0，，01：	1
	3	The Antinociceptive Effect of (-)-Linalool in Models of Chronic Inflammatory and Neuropathic Hypersensitivity in Mice显示文摘	Patricia Aparecida Batista Maria Fernanda de Paula Werner Erica Carvalho Oliveira Leonel Burgos Patricia Pereira Lucimar Filot da Silva Brum Gina M. Story Adair R.S. Santos	2010	Journal of Pain2010，，：	1
	4	A new for- malism for failure diagnosis: ant colony decision Petri nets显示文摘	Calin Ciufudean Adrian Graur Constantin Filote	2007	Journal of software2007，2，1：	1
	5	A new For- malism for Failure Diagnosis: Ant Colony Decision Petri Nets 显示文摘	Calin Ciufudean Adrian Graur Constantin Filote etc	2007	Journal of software2007，2，1：	1
	6	Rapid online equil- ibration method to determine the D/H ratios of non-exchange- able hydrogen in cellulose显示文摘	Filot M S Leuenberger M Pazdur A etal	2006	Rapid Communications in Mass Spectrometry2006，20，22：	1
	7	Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors显示文摘Background The utility of routine extensive molecular profiling of pediatric tumors is a matter of debate due to the high number of genetic alterations of unknown significance or low evidence and the lack of standardized and personalized decision support methods.Digital drug assignment(DDA)is a novel computational method to prioritize treatment options by aggregating numerous evidence-based associations between multiple drivers,targets,and targeted agents.DDA has been validated to improve personalized treatment decisions based on the outcome data of adult patients treated in the SHIVA01 clinical trial.The aim of this study was to evaluate the utility of DDA in pediatric oncology.Methods Between 2017 and 2020,103 high-risk pediatric cancer patients(<21 years)were involved in our precision oncology program,and samples from 100 patients were eligible for further analysis.Tissue or blood samples were analyzed by whole-exome(WES)or targeted panel sequencing and other molecular diagnostic modalities and processed by a software system using the DDA algorithm for therapeutic decision support.Finally,a molecular tumor board(MTB)evaluated the results to provide therapy recommendations.Results Of the 100 cases with comprehensive molecular diagnostic data,88 yielded WES and 12 panel sequencing results.DDA identified matching off-label targeted treatment options(actionability)in 72/100 cases(72%),while 57/100(57%)showed potential drug resistance.Actionability reached 88%(29/33)by 2020 due to the continuous updates of the evidence database.MTB approved the clinical use of a DDA-top-listed treatment in 56 of 72 actionable cases(78%).The approved therapies had significantly higher aggregated evidence levels(AELs)than dismissed therapies.Filtering of WES results for targeted panels missed important mutations affecting therapy selection.Conclusions DDA is a promising approach to overcome challenges associated with the interpretation of extensive molecular profiling in the routine care of high-risk pediatric cancers.Knowledgebase updates enable automatic interpretation of a continuously expanding gene set,a“virtual”panel,filtered out from genome-wide analysis to always maximize the performance of precision treatment planning.	Barbara Vodicska Júlia Déri Dóra Tihanyi Edit Várkondi EnikőKispéter Róbert Dóczi Dóra Lakatos Anna Dirner Mátyás Vidermann Péter Filotás Réka Szalkai-Dénes István Szegedi Katalin Bartyik Krisztina Míta Gábor Réka Simon Péter Hauser György Péter Csongor Kiss Miklós Garami István Peták	2023	World Journal of Pediatrics2023，19，10：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费